Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rapid Micro Biosystems (RPID) EBT (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed EBT for 6 consecutive years, with -$12.5 million as the latest value for Q4 2025.

  • Quarterly EBT fell 29.02% to -$12.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$47.1 million through Dec 2025, changed 0.46% year-over-year, with the annual reading at -$47.1 million for FY2025, 0.46% changed from the prior year.
  • EBT hit -$12.5 million in Q4 2025 for Rapid Micro Biosystems, down from -$11.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$9.7 million in Q4 2024 to a low of -$25.0 million in Q3 2021.
  • Historically, EBT has averaged -$14.1 million across 5 years, with a median of -$13.4 million in 2023.
  • Biggest five-year swings in EBT: tumbled 195.64% in 2021 and later soared 34.59% in 2022.
  • Year by year, EBT stood at -$14.6 million in 2021, then fell by 12.83% to -$16.4 million in 2022, then surged by 32.09% to -$11.2 million in 2023, then rose by 13.34% to -$9.7 million in 2024, then dropped by 29.02% to -$12.5 million in 2025.
  • Business Quant data shows EBT for RPID at -$12.5 million in Q4 2025, -$11.5 million in Q3 2025, and -$11.8 million in Q2 2025.